Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Soleno Therapeutics (SLNO) Gross Margin (2016 - 2025)

Soleno Therapeutics (SLNO) has disclosed Gross Margin for 4 consecutive years, with 99.06% as the latest value for Q4 2025.

  • Quarterly Gross Margin changed N/A to 99.06% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 99.27% through Dec 2025, changed N/A year-over-year, with the annual reading at 98.58% for FY2025, N/A changed from the prior year.
  • Gross Margin for Q4 2025 was 99.06% at Soleno Therapeutics, up from 98.27% in the prior quarter.
  • The five-year high for Gross Margin was 99.06% in Q4 2025, with the low at 97.87% in Q2 2025.